Oxygen gas

Phase 3Small molecule

TThe Hospital for Sick Children

Oxygen gas is one of 159 small molecule programs targeting Hypovolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypovolemiaActive, not recruiting

Wound HealingActive, not recruiting

MortalityActive, not recruiting

Pulmonary EmbolismActive, not recruiting

Transposition of the Great ArteriesActive, not recruiting

COVID-19Active, not recruiting

Sleep ApneaActive, not recruiting

HypovolemiaPhase 1

Active, not recruiting

Wound HealingPreclinical

Active, not recruiting

MortalityPreclinical

Active, not recruiting

Pulmonary EmbolismPhase 3

Active, not recruiting

Transposition of the Great ArteriesPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Sleep ApneaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Oxygen gas

TThe Hospital for Sick Children

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Calciferol

Alnylam Pharmaceuticals

Tricor

1 5

Benadryl

PParkedale

Preclinical

1 6

Rayaldee

OOrganon and Co

Preclinical

1 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 8

Glucocorticoid

AbbVie

Preclinical

1 9

Nadroparin

GSK

Preclinical

1 10

Statins

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Sleep Apnea

NCT05237505

Clinical

Trials by Indication[1]

Mortality2 trials

Supplementary Oxygen in Surgical and Medical Wards Evaluated by 30-day Mortality

Completed·HHannibal Troensegaard··NCT03625700·11,196 enrolled

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation

Terminated·EEsbjerg Hospital - University Hospital of Southern Denmark·Phase 4·NCT04223050·23 enrolled

Percutaneous Coronary Intervention1 trial

Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen

Terminated·KKarolinska Institutet·Phase 3·NCT03369184·65 enrolled

Pulmonary Disease1 trial

Pulmonary Disease Requiring Ambulatory Oxygen Therapy -Resilience and Quality of Life

Unknown status·KKuopio University Hospital··NCT04554225·43 enrolled

Hypovolemia1 trial

Supplemental Oxygen in Hypovolemia

Completed·OOslo University Hospital·Phase 1·NCT05150418·15 enrolled

Cardiogenic Shock1 trial

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

Completed·—·Phase 3·NCT04990349·60 enrolled

5 more indications

Transposition of the Great Arteries1 trial

Acute Maternal Hyperoxygenation for Fetal Transposition of the Great Arteries (TGA)

Unknown status·TThe Hospital for Sick Children·N/A·NCT03771534·40 enrolled

COVID-191 trial

iNOPulse for COVID-19

Withdrawn·RRoger Alvarez·Phase 2·NCT04398290

Sleep Apnea1 trial

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

Recruiting·UUniversity of California, San Diego·Phase 2·NCT05237505·240 enrolled

Pulmonary Embolism1 trial

Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)

Completed·MMinistry of Health, Spain·Phase 3·NCT04003116·70 enrolled

Wound Healing1 trial

Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy

Completed·UUniversiti Sains Malaysia·N/A·NCT02344732·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Oxygen gas. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxygen gas compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxygen gas. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Hospital for Sick Children company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Hospital for Sick Children

Oxygen gas

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Mortality2 trials

Percutaneous Coronary Intervention1 trial

Pulmonary Disease1 trial

Hypovolemia1 trial

Cardiogenic Shock1 trial

Transposition of the Great Arteries1 trial

COVID-191 trial

Sleep Apnea1 trial

Pulmonary Embolism1 trial

Wound Healing1 trial

References

Drug Info

Quick Facts

Related News